RegulatoryOfficial

European Commission authorises Gedeon Richter's Inijaq, a new tofacitinib product

🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026

Commission Decision (2026) 8201 of 12 November 2026 grants marketing authorisation to Inijaq (tofacitinib), adding another tofacitinib medicine to the EU market.

The European Commission has granted a marketing authorisation to Inijaq, a tofacitinib-containing medicine from Gedeon Richter Plc. The authorisation was issued through Commission Decision (2026) 8201 of 12 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.

More Regulatory All →